Avalon GloboCare (ALBT) Competitors $2.39 0.00 (0.00%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$2.41 +0.02 (+0.84%) As of 10/8/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALBT vs. RANI, MURA, ADAP, EGRX, ATHE, TENX, SCYX, MAAQ, AKTX, and ITRMShould you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include Rani Therapeutics (RANI), Mural Oncology (MURA), Adaptimmune Therapeutics (ADAP), Eagle Pharmaceuticals (EGRX), Alterity Therapeutics (ATHE), Tenax Therapeutics (TENX), SCYNEXIS (SCYX), Mana Capital Acquisition (MAAQ), Akari Therapeutics (AKTX), and Iterum Therapeutics (ITRM). These companies are all part of the "pharmaceutical products" industry. Avalon GloboCare vs. Its Competitors Rani Therapeutics Mural Oncology Adaptimmune Therapeutics Eagle Pharmaceuticals Alterity Therapeutics Tenax Therapeutics SCYNEXIS Mana Capital Acquisition Akari Therapeutics Iterum Therapeutics Avalon GloboCare (NASDAQ:ALBT) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings. Which has more risk and volatility, ALBT or RANI? Avalon GloboCare has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of -0.02, suggesting that its share price is 102% less volatile than the S&P 500. Does the media refer more to ALBT or RANI? In the previous week, Avalon GloboCare had 3 more articles in the media than Rani Therapeutics. MarketBeat recorded 3 mentions for Avalon GloboCare and 0 mentions for Rani Therapeutics. Avalon GloboCare's average media sentiment score of 0.49 beat Rani Therapeutics' score of 0.00 indicating that Avalon GloboCare is being referred to more favorably in the media. Company Overall Sentiment Avalon GloboCare Neutral Rani Therapeutics Neutral Do analysts prefer ALBT or RANI? Rani Therapeutics has a consensus target price of $7.33, suggesting a potential upside of 1,396.29%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Rani Therapeutics is more favorable than Avalon GloboCare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Rani Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has stronger valuation and earnings, ALBT or RANI? Avalon GloboCare has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalon GloboCare$1.39M6.59-$7.90M-$19.96-0.12Rani Therapeutics$1.20M29.35-$30.02M-$0.91-0.54 Is ALBT or RANI more profitable? Rani Therapeutics has a net margin of 0.00% compared to Avalon GloboCare's net margin of -1,451.94%. Avalon GloboCare's return on equity of 0.00% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avalon GloboCare-1,451.94% N/A -75.12% Rani Therapeutics N/A -1,258.76%-97.97% Do insiders & institutionals have more ownership in ALBT or RANI? 1.4% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 37.3% of Avalon GloboCare shares are owned by insiders. Comparatively, 45.1% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryAvalon GloboCare and Rani Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Avalon GloboCare News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALBT vs. The Competition Export to ExcelMetricAvalon GloboCareMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.17M$3.35B$6.10B$10.55BDividend YieldN/A2.28%5.69%4.75%P/E Ratio-0.1221.5785.6027.60Price / Sales6.59273.73538.21205.12Price / CashN/A47.1237.9261.55Price / Book-0.2110.1413.246.76Net Income-$7.90M-$52.31M$3.30B$275.88M7 Day Performance6.22%5.14%4.35%2.81%1 Month Performance-4.40%14.68%9.51%9.24%1 Year Performance-24.74%30.98%88.04%35.42% Avalon GloboCare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALBTAvalon GloboCare1.6396 of 5 stars$2.39flatN/A-29.8%$9.17M$1.39M-0.125Analyst ForecastRANIRani Therapeutics2.6909 of 5 stars$0.50+2.7%$7.33+1,357.9%-77.6%$36.15M$1.20M-0.55110Analyst ForecastMURAMural Oncology3.3748 of 5 stars$2.09+0.2%$12.00+475.5%-40.1%$36.13MN/A-0.24119Analyst ForecastADAPAdaptimmune Therapeutics2.5044 of 5 stars$0.13-4.3%$1.35+908.7%-76.8%$35.78M$178.03M-0.21490News CoverageAnalyst ForecastGap UpEGRXEagle Pharmaceuticals1.4274 of 5 stars$2.70-4.4%N/A+445.5%$35.07M$257.55M0.00100ATHEAlterity Therapeutics2.5065 of 5 stars$3.86-2.2%$12.00+211.3%+226.5%$34.19MN/A0.0010Positive NewsAnalyst ForecastGap UpTENXTenax Therapeutics1.9718 of 5 stars$7.47+2.5%$18.00+141.0%+140.9%$34.09MN/A-8.129High Trading VolumeSCYXSCYNEXIS0.4443 of 5 stars$0.79-24.8%N/A-47.9%$33.33M$3.26M-1.9960Gap UpHigh Trading VolumeMAAQMana Capital AcquisitionN/A$4.07+0.2%N/A+1,886.4%$33.07MN/A0.001Gap UpAKTXAkari Therapeutics2.7196 of 5 stars$1.01-1.1%$3.30+226.7%-66.2%$32.95MN/A0.009Analyst ForecastGap DownITRMIterum Therapeutics1.4679 of 5 stars$0.68-0.6%$9.00+1,221.6%-20.2%$32.12MN/A-0.8010Analyst ForecastGap Up Related Companies and Tools Related Companies Rani Therapeutics Competitors Mural Oncology Competitors Adaptimmune Therapeutics Competitors Eagle Pharmaceuticals Competitors Alterity Therapeutics Competitors Tenax Therapeutics Competitors SCYNEXIS Competitors Mana Capital Acquisition Competitors Akari Therapeutics Competitors Iterum Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALBT) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalon GloboCare Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalon GloboCare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
